American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
Upgrade
American Flag

Acadia Pharmaceuticals Inc.

ACAD Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News

Chart provided by TradingView

ACAD historical prices
Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of ACAD by members of U.S. Congress

Politician Type Traded
Chris Jacobs House / R Sale $1,001 - $15,000 Jun 16, 2022
Chris Jacobs House / R Sale $1,001 - $15,000 Sep 08, 2020
Gilbert Ray Cisneros, Jr. House / D Sale $1,001 - $15,000 Feb 19, 2019
Ro Khanna House / D Sale $1,001 - $15,000 May 08, 2018
Ro Khanna House / D Purchase $1,001 - $15,000 Apr 03, 2018
ACAD Stock Insider Trading Activity Follow @QuiverQuant for major insider updates

---

Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
ACAD Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
ACAD Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in ACAD holdings by institutional investors

Insider Trading

Quarterly net insider trading by ACAD's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $700,000 Jul 20, 2026 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Trade (domestic/foreign)
  • $600,000 Apr 20, 2026 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
  • $590,000 Jan 19, 2026 Issue: Medicare/Medicaid Taxation/Internal Revenue Code Health Issues
  • $750,000 Oct 19, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
  • $500,000 Jul 21, 2025 Issue: Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
  • $440,000 Apr 18, 2025 Issue: Health Issues Medicare/Medicaid Taxation/Internal Revenue Code
  • $510,000 Jan 19, 2025 Issue: Health Issues Medicare/Medicaid Trade (domestic/foreign) Taxation/Internal Revenue Code
  • $220,000 Oct 21, 2024 Issue: Trade (domestic/foreign) Medicare/Medicaid Health Issues
  • $450,000 Jul 22, 2024 Issue: Medicare/Medicaid Health Issues
  • $240,000 Jan 19, 2024 Issue: Medicare/Medicaid Health Issues
  • $180,000 Oct 18, 2023 Issue: Medicare/Medicaid Health Issues
  • $230,000 Jul 20, 2023 Issue: Medicare/Medicaid Health Issues
  • $370,000 Jan 19, 2023 Issue: Defense Budget/Appropriations Medicare/Medicaid Health Issues
  • $260,000 Oct 19, 2022 Issue: Defense Budget/Appropriations Medicare/Medicaid Health Issues
  • $310,000 Aug 18, 2022 Issue: None
  • $230,000 Jul 20, 2022 Issue: Medicare/Medicaid Health Issues
  • $200,000 Jan 20, 2022 Issue: None
  • $210,000 Oct 19, 2021 Issue: None
  • $210,000 Jul 19, 2021 Issue: None
  • $220,000 Apr 20, 2021 Issue: None
  • $190,000 Jan 20, 2021 Issue: None
  • $10,000 Oct 16, 2020 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid
  • $10,000 Jul 15, 2020 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
  • $20,000 Apr 16, 2020 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid
  • $20,000 Jan 21, 2020 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
  • $20,000 Oct 21, 2019 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
  • $20,000 Jul 22, 2019 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
  • $20,000 Apr 22, 2019 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
  • $20,000 Jan 22, 2019 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs
  • $20,000 Oct 22, 2018 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid
Revolving Door

Former government officials who have lobbied for ACAD

13 former government officials from 7 congressional offices at 5 lobbying firms have lobbied for ACAD, most recently Apr 16, 2026.

  • Jon C. Porter
    Alanna Temme House Legislative Director, U.S. Representative Jon Porter Formerly with Jon C. Porter · LMH STRATEGIC SOLUTIONS · Apr 16, 2026
  • Tim Hutchinson
    Darin Gardner Senate Legislative Correspondent to Senator Tim Hutchinson; Research Assistant for Senate HELP Committee; Chief of Staff for Congresswoman Kay Granger Formerly with Tim Hutchinson · THE CONAFAY GROUP, LLC · Jan 20, 2026
  • John Cornyn
    Andrew Siracuse Senate New Sr. Tax Cnsl., Sen. John Cornyn; Staff Dir., Sen. Fin. Cmte. Int'l. Trade, Customs & Global Comp. Sbcmte., Tax Cnsl., Sen. Cornyn; Cnsl. Sen. Cornyn; Staff Dir. Sen. Fin. Cmte, Energy, Nat. Res. Sbcmte.; LA, Sen. Cornyn; LA, Sen. Norm Coleman Formerly with John Cornyn · HOLLAND & KNIGHT LLP · Oct 15, 2025
  • Tom Price
    John Twomey House New Chief of Staff, HHS Office of the Asst. Sec. for Legislation (2019-2021); Policy Adviser, HHS (2017-2019); Special Asst., Office of the Secretary, HHS (2017); Staff Assistant, Rep. Tom Price (2015-2017); Intern, Rep. Doug Collins (2015) Formerly with Tom Price · TIBER CREEK GROUP · Jan 20, 2025
  • Joshua Odintz Senate New Tax Counsel, Senate Finance Committee Formerly Tax Counsel, Senate Finance Committee · HOLLAND & KNIGHT LLP · Jan 09, 2025
  • Bryan Shuy House New Chief of Staff Rep. Harris; Asst. to Rep. Harris, House Cmte on Approps; Dep. Asst. Sec and Chief of Staff HHS/Asst. Secretary for Preparedness and Response (ASPR) Formerly Harris · THE CONAFAY GROUP, LLC · Jul 20, 2023
  • Corey Malmgren Congress New Sen. Bill Nelson, Deputy Legislative Director & Health Counsel (2015-2018); Rep. Sandy Levin, Legislative Counsel (2013-2015), Legislative Correspondent, Staff Assistant (2008-2009); House Committee on Ways and Means, Legal Clerk/Intern (2010) Formerly Bill Nelson · TIBER CREEK GROUP · Oct 15, 2021
  • Bryant Hall Senate New Staff Director, Sen. Veterans Affairs Committee (2003-2004); Legislative Director, Sen. Bob Graham (1999-2003) Formerly Veterans Affairs Committee · TIBER CREEK GROUP · Apr 19, 2021
See all 13 on the Revolving Door dashboard
Corporate Lobbying

ACAD Estimated quarterly lobbying spending

Revenue Breakdown

ACAD Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
ACAD Income Statement
ACAD Balance Sheet
ACAD Cash Flow
U.S. Patents

New ACAD patent grants

  • Patent Title: Single-layer oral dose of neuro-attenuating ketamine Feb. 24, 2026
  • Patent Title: Crystalline forms of trofinetide Dec. 09, 2025
  • Patent Title: Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods Nov. 11, 2025
  • Patent Title: Compounds, salts thereof and methods for treatment of diseases Nov. 12, 2024
  • Patent Title: Agitation process for preparing a carbetocin drug product Dec. 19, 2023
  • Patent Title: Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c Dec. 12, 2023
  • Patent Title: Crystalline forms of trofinetide Nov. 28, 2023
  • Patent Title: Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis Oct. 11, 2022
  • Patent Title: Formulations of pimavanserin Sep. 27, 2022
  • Patent Title: Compounds, salts thereof and methods for treatment of diseases Sep. 13, 2022
  • Patent Title: Compounds, salts thereof and methods for treatment of diseases May. 31, 2022
  • Patent Title: Combination of pimavanserin and cytochrome p450 modulators Dec. 07, 2021
  • Patent Title: Manufacturing methods and polymorphs of a thiazoline anti-hyperalgesic agent Nov. 02, 2021
  • Patent Title: Pimavanserin for treating impulse control disorder Oct. 05, 2021
  • Patent Title: Compounds for pain treatment, compositions comprising same, and methods of using same Aug. 17, 2021
  • Patent Title: Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c Apr. 20, 2021
  • Patent Title: Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form Apr. 20, 2021
  • Patent Title: Methods of treatment using selective 5-ht2a inverse agonists Sep. 19, 2017
  • Patent Title: Methods for the treatment of parkinson's disease psychosis using pimavanserin Sep. 12, 2017
  • Patent Title: Muscarinic agonists Jun. 06, 2017
  • Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Feb. 14, 2017
  • Patent Title: Tetrahydroquinoline analogues as muscarinic agonists Dec. 20, 2016
  • Patent Title: Methods for the treatment of parkinson's disease psychosis using pimavanserin Sep. 20, 2016
  • Patent Title: Azacyclic compounds Mar. 29, 2016
  • Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Dec. 15, 2015
  • Patent Title: Diphenyl substituted cyclohexane derivatives, useful as modulators of the estrogen receptors beta Jun. 23, 2015
  • Patent Title: Combination of pimavanserin and risperidone for the treatment of psychosis Jun. 09, 2015
  • Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Dec. 30, 2014
  • Patent Title: Compounds with activity at estrogen receptors Sep. 02, 2014
  • Patent Title: Tetrahydroquinoline analogues as muscarinic agonists Mar. 25, 2014
  • Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Dec. 31, 2013
  • Patent Title: Compounds with activity at estrogen receptors Jun. 25, 2013
  • Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Feb. 19, 2013
  • Patent Title: Synthesis of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms Aug. 07, 2012
  • Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Jul. 24, 2012
  • Patent Title: Compounds with activity at estrogen receptors Jan. 24, 2012
  • Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Aug. 30, 2011
  • Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Aug. 09, 2011
  • Patent Title: Synthesis of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms Apr. 12, 2011
  • Patent Title: Selective serotonin receptor inverse agonists as therapeutics for disease Jan. 25, 2011
  • Patent Title: Salts of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-y1)-n′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation Jan. 11, 2011
  • Patent Title: Selective serotonin receptor inverse agonists as therapeutics for disease Jan. 04, 2011
  • Patent Title: Compounds with activity at estrogen receptors Nov. 02, 2010
  • Patent Title: Selective serotonin receptor inverse agonists as therapeutics for disease Oct. 26, 2010
  • Patent Title: Synthesis of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms Sep. 07, 2010
  • Patent Title: N-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms Jun. 08, 2010
  • Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Jun. 08, 2010
  • Patent Title: Spiroazacyclic compounds as monoamine receptor modulators Jun. 01, 2010
  • Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases May. 11, 2010
  • Patent Title: Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases Feb. 09, 2010
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded to ACAD from public contracts

ACAD News

Recent insights relating to ACAD

CNBC Recommendations

Recent picks made for ACAD stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ACAD

ACAD Analyst Ratings

ACAD Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
ACAD Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $ACAD stock a Buy, Sell, or Hold?

  • What is the price target for $ACAD stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

ACAD Top Shareholders
Shareholder
Shares Held
ACAD Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $ACAD stock?

  • Who owns the most shares of $ACAD stock?

  • What funds own $ACAD stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

ACAD Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view ACAD Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About ACAD

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

  • Address San Diego, CA
  • Market Cap 3.8 billion
  • Employees 798
  • Industrial Classification Pharmaceutical Preparations

Acadia Pharmaceuticals Inc. (ACAD) Historical Stock Prices

Acadia Pharmaceuticals Inc. (ACAD) closed at $22.18 on September 24, 2026. Over the past year its adjusted close ranged from $20.06 to $30.57. Daily prices go back to January 2, 2014, 3,199 trading days in all.

  • 1 month-27.45%
  • 3 months-6.49%
  • Year to date-16.96%
  • 1 year+4.33%
  • 3 years-4.77%
  • 5 years+30.93%
  • Max-11.81%
See every congressional and insider trade on the ACAD price chart

Quiver Premium charts ACAD's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.

Upgrade to Premium

Last 12 months, newest first

Access Raw Data Daily prices since 2014 for every ticker, through the Quiver API
DateOpenHighLowCloseAdj. CloseVolume
Sep 24, 2026 24.38 24.38 21.97 22.18 22.18 6,761,623
Sep 23, 2026 26.41 26.51 24.93 25.43 25.43 1,306,066
Sep 22, 2026 26.65 26.86 26.32 26.41 26.41 1,472,449
Sep 21, 2026 27.43 27.43 26.34 26.39 26.39 1,351,979
Sep 18, 2026 27.37 27.48 26.73 27.29 27.29 5,482,812
Sep 17, 2026 27.78 28.06 27.29 27.45 27.45 1,307,767
Sep 16, 2026 26.75 27.60 26.66 27.54 27.54 1,405,152
Sep 15, 2026 27.51 27.51 26.64 26.76 26.76 1,109,419
Sep 14, 2026 28.00 28.10 27.38 27.52 27.52 1,628,513
Sep 11, 2026 27.98 28.24 27.74 27.83 27.83 1,172,902
Sep 10, 2026 27.63 27.86 27.36 27.74 27.74 1,014,565
Sep 9, 2026 27.44 27.95 27.40 27.68 27.68 1,293,919
Sep 8, 2026 27.63 28.09 27.10 27.58 27.58 1,457,760
Sep 4, 2026 27.77 28.19 27.65 28.02 28.02 1,682,950
Sep 3, 2026 29.00 29.07 27.61 27.86 27.86 1,849,411
Sep 2, 2026 29.10 29.75 28.88 28.93 28.93 1,555,986
Sep 1, 2026 28.84 29.30 28.51 28.89 28.89 830,928
Aug 31, 2026 29.05 29.12 28.57 28.91 28.91 1,035,961
Aug 28, 2026 29.51 29.73 29.02 29.11 29.11 1,529,974
Aug 27, 2026 29.26 29.83 29.15 29.73 29.73 879,365
Aug 26, 2026 30.36 30.38 29.28 29.58 29.58 1,336,189
Aug 25, 2026 30.14 30.76 29.84 30.57 30.57 1,523,784
Aug 24, 2026 29.50 29.77 29.15 29.65 29.65 1,489,609
Aug 21, 2026 29.08 29.61 28.80 29.50 29.50 1,093,516
Aug 20, 2026 30.00 30.00 28.95 29.04 29.04 1,318,712
Aug 19, 2026 30.66 30.96 30.07 30.21 30.21 2,288,067
Aug 18, 2026 29.14 30.25 29.05 30.18 30.18 2,053,504
Aug 17, 2026 28.63 29.03 28.21 29.01 29.01 1,122,499
Aug 14, 2026 28.26 28.43 27.90 28.24 28.24 1,062,578
Aug 13, 2026 29.75 29.75 28.36 28.38 28.38 1,507,221
Aug 12, 2026 29.18 29.85 28.83 29.45 29.45 1,409,739
Aug 11, 2026 29.57 29.76 29.09 29.41 29.41 1,346,523
Aug 10, 2026 29.00 29.65 29.00 29.39 29.39 2,726,434
Aug 7, 2026 28.57 29.29 28.20 29.21 29.21 1,782,723
Aug 6, 2026 28.85 29.48 28.32 28.45 28.45 3,049,755
Aug 5, 2026 27.95 29.16 27.80 28.80 28.80 4,549,297
Aug 4, 2026 25.66 27.23 25.55 27.15 27.15 2,440,393
Aug 3, 2026 25.96 26.11 25.43 25.61 25.61 1,368,071
Jul 31, 2026 26.44 26.44 25.34 25.87 25.87 1,534,224
Jul 30, 2026 26.13 26.58 25.87 26.55 26.55 1,298,677
Jul 29, 2026 26.12 26.54 25.82 26.34 26.34 1,733,147
Jul 28, 2026 25.52 26.08 25.52 26.01 26.01 940,899
Jul 27, 2026 25.22 25.78 24.99 25.39 25.39 1,399,666
Jul 24, 2026 24.90 25.10 24.57 24.84 24.84 1,046,976
Jul 23, 2026 24.23 25.00 24.23 24.83 24.83 1,272,018
Jul 22, 2026 25.62 25.62 24.91 24.96 24.96 1,163,336
Jul 21, 2026 25.20 25.57 25.07 25.43 25.43 1,340,502
Jul 20, 2026 26.07 26.16 25.03 25.09 25.09 1,486,529
Jul 17, 2026 25.37 25.84 25.20 25.60 25.60 1,207,375
Jul 16, 2026 25.94 26.23 25.47 25.63 25.63 2,189,326
Jul 15, 2026 25.38 26.08 25.18 25.92 25.92 1,274,099
Jul 14, 2026 25.58 25.64 24.95 25.49 25.49 1,221,006
Jul 13, 2026 26.04 26.04 25.30 25.50 25.50 1,562,833
Jul 10, 2026 26.51 26.51 25.66 26.22 26.22 1,442,787
Jul 9, 2026 25.70 26.51 25.59 26.41 26.41 1,801,279
Jul 8, 2026 26.15 26.29 25.59 26.00 26.00 1,551,853
Jul 7, 2026 26.16 26.35 25.63 26.20 26.20 1,674,460
Jul 6, 2026 25.80 26.00 25.24 25.77 25.77 1,155,022
Jul 2, 2026 25.41 26.23 25.13 25.97 25.97 1,586,395
Jul 1, 2026 25.24 25.55 24.93 25.20 25.20 1,417,658
Jun 30, 2026 25.34 26.00 25.02 25.30 25.30 1,721,284
Jun 29, 2026 25.40 25.73 24.95 25.20 25.20 2,090,012
Jun 26, 2026 26.38 27.31 25.07 25.32 25.32 7,370,513
Jun 25, 2026 23.28 24.11 23.28 23.72 23.72 1,491,648
Jun 24, 2026 22.67 23.79 22.67 23.36 23.36 1,495,872
Jun 23, 2026 22.26 22.66 22.01 22.60 22.60 1,476,896
Jun 22, 2026 21.64 22.46 21.59 22.09 22.09 1,904,396
Jun 18, 2026 21.73 21.90 21.20 21.62 21.62 3,225,716
Jun 17, 2026 20.99 21.73 20.92 21.60 21.60 1,340,344
Jun 16, 2026 21.34 21.47 20.84 20.94 20.94 1,242,241
Jun 15, 2026 21.10 21.39 21.05 21.27 21.27 1,209,891
Jun 12, 2026 21.49 21.55 21.05 21.09 21.09 753,938
Jun 11, 2026 21.12 21.68 20.92 21.39 21.39 945,147
Jun 10, 2026 21.79 22.14 21.23 21.25 21.25 1,231,797
Jun 9, 2026 21.86 22.03 21.47 21.84 21.84 1,104,695
Jun 8, 2026 21.56 21.79 21.27 21.70 21.70 883,774
Jun 5, 2026 21.71 21.96 21.45 21.56 21.56 807,264
Jun 4, 2026 21.72 21.85 21.48 21.72 21.72 1,122,690
Jun 3, 2026 20.87 21.44 20.76 21.43 21.43 1,282,278
Jun 2, 2026 21.27 21.38 20.75 20.89 20.89 1,236,277
Jun 1, 2026 21.40 21.60 20.96 21.52 21.52 1,119,174
May 29, 2026 21.65 21.95 21.58 21.66 21.66 1,745,373
May 28, 2026 21.00 21.82 20.89 21.63 21.63 1,075,593
May 27, 2026 21.48 21.60 21.14 21.19 21.19 982,349
May 26, 2026 21.07 21.27 20.91 21.26 21.26 964,968
May 22, 2026 21.16 21.60 21.07 21.10 21.10 1,376,987
May 21, 2026 20.64 21.47 20.41 21.32 21.32 1,664,475
May 20, 2026 20.48 21.00 20.48 20.95 20.95 1,704,815
May 19, 2026 20.69 20.91 20.30 20.48 20.48 2,089,324
May 18, 2026 21.45 21.68 20.65 20.69 20.69 1,623,325
May 15, 2026 21.92 22.00 21.36 21.40 21.40 1,292,644
May 14, 2026 22.25 22.39 21.88 22.09 22.09 2,029,032
May 13, 2026 21.57 22.27 21.41 22.18 22.18 1,543,120
May 12, 2026 21.88 22.10 21.57 21.72 21.72 1,125,205
May 11, 2026 22.10 22.50 21.75 21.80 21.80 1,944,009
May 8, 2026 22.43 22.91 22.26 22.40 22.40 2,084,365
May 7, 2026 21.89 22.84 21.52 22.56 22.56 3,670,142
May 6, 2026 22.54 23.07 21.36 21.48 21.48 3,577,886
May 5, 2026 22.38 22.70 22.12 22.35 22.35 1,030,988
May 4, 2026 21.79 22.28 21.64 22.19 22.19 1,907,785
May 1, 2026 22.31 22.34 21.63 21.95 21.95 1,449,400
Apr 30, 2026 22.20 22.72 22.19 22.45 22.45 1,734,912
Apr 29, 2026 22.36 22.73 22.01 22.20 22.20 1,321,853
Apr 28, 2026 22.46 22.78 22.30 22.67 22.67 1,319,186
Apr 27, 2026 21.90 22.79 21.90 22.30 22.30 1,075,540
Apr 24, 2026 22.03 22.23 21.67 21.96 21.96 868,162
Apr 23, 2026 22.22 22.23 21.84 22.11 22.11 1,209,552
Apr 22, 2026 21.98 22.36 21.81 22.24 22.24 1,180,194
Apr 21, 2026 22.11 22.18 21.70 21.80 21.80 991,721
Apr 20, 2026 22.13 22.37 21.95 22.09 22.09 1,037,484
Apr 17, 2026 21.85 22.29 21.66 22.17 22.17 8,552,566
Apr 16, 2026 21.86 22.07 21.16 21.25 21.25 1,677,626
Apr 15, 2026 22.02 22.32 21.72 21.76 21.76 1,232,953
Apr 14, 2026 21.46 22.13 21.46 22.02 22.02 1,972,975
Apr 13, 2026 21.53 21.66 20.96 21.46 21.46 2,038,017
Apr 10, 2026 22.52 22.59 21.42 21.74 21.74 849,310
Apr 9, 2026 22.35 22.66 22.09 22.57 22.57 1,229,430
Apr 8, 2026 22.85 22.86 22.39 22.56 22.56 1,640,623
Apr 7, 2026 22.20 22.31 21.90 22.09 22.09 1,429,599
Apr 6, 2026 21.99 22.74 21.99 22.32 22.32 1,298,586
Apr 2, 2026 21.85 22.48 21.71 22.20 22.20 1,702,906
Apr 1, 2026 22.22 22.89 21.99 22.32 22.32 1,612,729
Mar 31, 2026 21.26 22.39 21.26 22.26 22.26 2,211,240
Mar 30, 2026 21.16 21.16 20.67 21.07 21.07 1,724,351
Mar 27, 2026 21.25 21.42 20.75 20.75 20.75 1,215,028
Mar 26, 2026 21.65 21.94 21.43 21.47 21.47 1,466,305
Mar 25, 2026 21.40 22.36 21.40 22.01 22.01 2,357,271
Mar 24, 2026 20.82 21.07 20.36 20.96 20.96 1,989,930
Mar 23, 2026 21.32 21.51 20.94 20.99 20.99 1,414,578
Mar 20, 2026 20.69 21.06 20.59 20.74 20.74 3,343,584
Mar 19, 2026 20.09 20.89 19.89 20.72 20.72 2,419,863
Mar 18, 2026 20.80 20.80 20.12 20.32 20.32 2,562,842
Mar 17, 2026 21.39 21.62 20.81 20.90 20.90 2,423,444
Mar 16, 2026 21.04 21.54 20.94 21.39 21.39 3,050,142
Mar 13, 2026 21.41 21.57 20.54 20.61 20.61 1,553,287
Mar 12, 2026 21.54 21.81 21.19 21.27 21.27 1,350,913
Mar 11, 2026 22.32 22.49 21.77 21.97 21.97 1,135,917
Mar 10, 2026 22.52 22.91 22.28 22.54 22.54 1,251,949
Mar 9, 2026 21.94 22.62 21.51 22.58 22.58 1,753,162
Mar 6, 2026 22.04 22.31 21.63 22.16 22.16 1,324,043
Mar 5, 2026 22.87 23.13 22.08 22.40 22.40 2,209,019
Mar 4, 2026 23.05 23.46 22.14 23.39 23.39 1,927,324
Mar 3, 2026 22.34 22.96 22.28 22.50 22.50 1,974,894
Mar 2, 2026 24.21 24.34 22.73 22.81 22.81 3,027,163
Feb 27, 2026 24.34 25.36 24.21 24.56 24.56 1,797,172
Feb 26, 2026 23.64 25.04 22.46 24.64 24.64 3,972,525
Feb 25, 2026 24.64 25.10 24.30 24.97 24.97 1,797,644
Feb 24, 2026 25.04 25.19 24.49 24.59 24.59 1,500,777
Feb 23, 2026 24.78 24.97 23.98 24.73 24.73 2,901,230
Feb 20, 2026 24.01 24.22 23.58 23.99 23.99 2,246,924
Feb 19, 2026 23.04 24.56 22.88 24.33 24.33 1,924,344
Feb 18, 2026 22.80 23.27 22.59 23.20 23.20 1,090,866
Feb 17, 2026 21.94 23.06 21.90 22.95 22.95 1,806,089
Feb 13, 2026 21.89 22.19 21.79 22.03 22.03 985,351
Feb 12, 2026 22.46 22.58 21.51 21.61 21.61 1,237,508
Feb 11, 2026 22.89 22.92 22.15 22.47 22.47 977,515
Feb 10, 2026 23.14 23.26 22.66 22.70 22.70 1,313,925
Feb 9, 2026 23.38 23.54 23.02 23.22 23.22 1,549,531
Feb 6, 2026 24.04 24.04 23.37 23.56 23.56 2,355,891
Feb 5, 2026 24.50 24.67 23.37 23.46 23.46 1,184,641
Feb 4, 2026 24.82 24.95 24.16 24.23 24.23 1,476,652
Feb 3, 2026 25.69 25.90 24.42 24.76 24.76 1,808,035
Feb 2, 2026 25.29 26.23 25.03 26.13 26.13 1,332,034
Jan 30, 2026 25.59 25.77 25.06 25.13 25.13 1,210,244
Jan 29, 2026 25.62 26.04 25.47 25.70 25.70 1,055,038
Jan 28, 2026 26.36 27.20 25.52 25.62 25.62 1,500,888
Jan 27, 2026 26.82 27.22 25.71 26.20 26.20 1,075,691
Jan 26, 2026 26.58 27.08 26.43 26.86 26.86 596,282
Jan 23, 2026 27.41 27.81 26.66 26.84 26.84 1,951,217
Jan 22, 2026 26.67 27.68 26.67 27.51 27.51 1,611,245
Jan 21, 2026 26.14 26.95 26.05 26.76 26.76 1,374,099
Jan 20, 2026 25.72 26.32 25.25 26.29 26.29 1,248,808
Jan 16, 2026 26.70 26.70 25.81 25.99 25.99 1,357,728
Jan 15, 2026 26.99 27.06 26.42 26.53 26.53 998,179
Jan 14, 2026 26.52 26.87 26.34 26.86 26.86 951,832
Jan 13, 2026 26.96 26.98 26.01 26.46 26.46 1,141,107
Jan 12, 2026 26.50 26.73 25.90 26.59 26.59 1,046,945
Jan 9, 2026 26.94 27.20 26.49 26.78 26.78 756,941
Jan 8, 2026 27.31 27.50 26.55 26.91 26.91 1,303,407
Jan 7, 2026 27.12 27.74 27.05 27.42 27.42 1,614,014
Jan 6, 2026 26.50 26.98 26.36 26.94 26.94 1,411,341
Jan 5, 2026 26.17 26.60 25.56 26.15 26.15 1,427,367
Jan 2, 2026 26.75 26.90 26.08 26.29 26.29 1,666,166
Dec 31, 2025 26.70 26.87 26.64 26.71 26.71 768,368
Dec 30, 2025 27.12 27.30 26.66 26.70 26.70 1,048,061
Dec 29, 2025 27.53 27.62 27.07 27.26 27.26 995,865
Dec 26, 2025 27.95 27.95 27.40 27.62 27.62 626,466
Dec 24, 2025 27.95 27.96 27.65 27.87 27.87 500,089
Dec 23, 2025 28.03 28.35 27.58 27.83 27.83 1,034,399
Dec 22, 2025 27.16 28.26 26.92 28.06 28.06 1,608,678
Dec 19, 2025 26.81 27.51 26.56 27.16 27.16 3,363,833
Dec 18, 2025 26.96 27.21 26.59 26.60 26.60 1,285,850
Dec 17, 2025 26.77 27.35 26.60 26.93 26.93 1,447,392
Dec 16, 2025 27.29 27.47 26.59 26.80 26.80 1,547,318
Dec 15, 2025 27.18 27.46 26.82 27.26 27.26 1,387,583
Dec 12, 2025 26.75 27.28 26.42 27.15 27.15 1,399,090
Dec 11, 2025 26.67 26.97 26.38 26.68 26.68 940,497
Dec 10, 2025 26.87 27.07 26.55 26.81 26.81 1,731,820
Dec 9, 2025 26.76 27.66 26.70 26.89 26.89 1,910,021
Dec 8, 2025 27.67 27.73 26.60 26.76 26.76 1,614,368
Dec 5, 2025 26.75 27.61 26.74 27.44 27.44 2,122,475
Dec 4, 2025 25.57 26.76 25.40 26.55 26.55 1,812,130
Dec 3, 2025 25.51 26.12 25.29 25.88 25.88 1,436,234
Dec 2, 2025 25.24 25.68 24.87 25.43 25.43 1,726,438
Dec 1, 2025 24.74 25.21 24.59 24.85 24.85 1,077,163
Nov 28, 2025 24.93 25.12 24.56 25.04 25.04 563,252
Nov 26, 2025 24.22 25.20 24.20 24.81 24.81 1,880,081
Nov 25, 2025 24.07 24.66 24.00 24.39 24.39 1,143,446
Nov 24, 2025 23.57 23.93 23.10 23.90 23.90 1,837,394
Nov 21, 2025 23.04 23.98 22.84 23.56 23.56 1,353,669
Nov 20, 2025 23.49 23.61 22.81 22.90 22.90 1,148,764
Nov 19, 2025 23.61 23.73 22.85 23.10 23.10 1,449,537
Nov 18, 2025 23.69 24.07 23.50 23.80 23.80 1,613,746
Nov 17, 2025 23.65 24.50 23.34 24.01 24.01 1,207,113
Nov 14, 2025 23.29 24.11 23.20 24.02 24.02 1,241,111
Nov 13, 2025 23.96 24.39 23.49 23.64 23.64 2,046,048
Nov 12, 2025 23.48 24.39 23.38 24.13 24.13 2,390,569
Nov 11, 2025 22.14 23.83 22.00 23.72 23.72 1,673,552
Nov 10, 2025 22.80 22.89 22.08 22.20 22.20 1,432,059
Nov 7, 2025 21.88 22.73 21.61 22.57 22.57 1,558,901
Nov 6, 2025 23.58 23.58 20.64 21.65 21.65 2,314,251
Nov 5, 2025 21.76 22.52 21.68 22.33 22.33 2,342,153
Nov 4, 2025 21.98 22.20 21.72 21.85 21.85 1,385,840
Nov 3, 2025 22.50 22.78 21.87 22.37 22.37 1,815,849
Oct 31, 2025 22.55 22.91 22.25 22.70 22.70 1,416,277
Oct 30, 2025 22.24 22.88 22.15 22.74 22.74 1,190,343
Oct 29, 2025 22.55 22.92 22.05 22.53 22.53 2,081,368
Oct 28, 2025 22.99 23.05 22.55 22.62 22.62 1,330,735
Oct 27, 2025 22.25 23.01 21.96 22.99 22.99 2,210,764
Oct 24, 2025 21.81 22.19 21.48 22.02 22.02 1,383,780
Oct 23, 2025 21.27 21.75 21.07 21.73 21.73 1,621,214
Oct 22, 2025 21.27 21.41 20.88 21.39 21.39 1,461,722
Oct 21, 2025 21.14 21.35 20.81 21.27 21.27 1,515,268
Oct 20, 2025 21.05 21.34 20.75 20.94 20.94 1,660,479
Oct 17, 2025 20.46 21.07 20.33 20.89 20.89 2,115,920
Oct 16, 2025 21.79 22.10 20.46 20.62 20.62 2,807,128
Oct 15, 2025 20.41 21.92 20.41 21.74 21.74 2,753,391
Oct 14, 2025 19.86 20.47 19.72 20.36 20.36 2,571,054
Oct 13, 2025 20.59 20.77 19.69 20.06 20.06 2,568,773
Oct 10, 2025 20.96 20.96 20.02 20.06 20.06 2,854,316
Oct 9, 2025 21.27 21.33 20.57 20.63 20.63 1,993,754
Oct 8, 2025 21.71 21.71 21.19 21.31 21.31 1,817,163
Oct 7, 2025 21.61 21.95 21.42 21.54 21.54 2,244,203
Oct 6, 2025 21.80 21.94 21.32 21.59 21.59 2,178,261
Oct 3, 2025 21.47 21.85 21.42 21.80 21.80 1,346,726
Oct 2, 2025 21.28 21.49 21.07 21.38 21.38 1,690,271
Oct 1, 2025 21.33 21.55 21.00 21.24 21.24 2,035,687
Sep 30, 2025 21.46 21.48 20.87 21.34 21.34 1,969,055
Sep 29, 2025 21.27 21.53 21.04 21.32 21.32 1,870,383
Sep 26, 2025 21.25 21.40 20.92 21.05 21.05 2,927,421
Sep 25, 2025 21.19 21.36 20.85 21.21 21.21 2,777,582
Sep 24, 2025 20.82 21.86 20.02 21.26 21.26 8,441,554

Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.

Need daily prices for every ticker, in code?

The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.

Explore the Quiver API
Acadia Pharmaceuticals Inc. Executive Compensation

We estimate that -- received a compensation of -- in --, making them the highest paid executive at ACAD, per a recent SEC DEF 14A filing. We estimate that the median employee at ACADIA PHARMACEUTICALS INC is paid $340,972.



Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation